electrancy(@electrancy) 's Twitter Profile Photo

'MGM distributions' made a copyright claim on 8 seconds of an original song I submitted to my YouTube channel I started a year ago. Have you ever had this happen? I could dispute it, but apparently it's a lengthy process and I'm wondering if it's worth it. What would you do?

account_circle
Florian J. Fintelmann(@F_Fintelmann_MD) 's Twitter Profile Photo

Patients with have severely limited options for treating . 🙌 to my PostDoc for showing that ❄️cryoablation of stage IA NSCLC is well tolerated in . No ILD exacerbations within 90d + PFS 97% at 1year OncoAlert

Patients with #interstitialLungDisease have severely limited options for treating #lungcancer. 🙌 to my PostDoc for showing that ❄️cryoablation of stage IA NSCLC is well tolerated in #interstitialLungDisease. No ILD exacerbations within 90d + PFS 97% at 1year @OncoAlert
account_circle
ERS publications(@ERSpublications) 's Twitter Profile Photo

ERJ: Rituximab plus MMF is associated with benefits in lung function and progression-free survival compared with MMF plus placebo after 24 weeks of treatment. The safety profile of rituximab plus MMF was similar to that of MMF plus placebo. bit.ly/3zcozku

ERJ: Rituximab plus MMF is associated with benefits in lung function and progression-free survival compared with MMF plus placebo after 24 weeks of treatment. The safety profile of rituximab plus MMF was similar to that of MMF plus placebo. bit.ly/3zcozku
account_circle
Leticia Kawano-Dourado 🇧🇷🇵🇹(@leticiakawano) 's Twitter Profile Photo

1/Amazing progress (Dx & Rx) has been made in the field of ILD.
That fills us w enthusiasm & hope to keep working to . But, when we looked carefully at the teams driving all these changes, we were surprised:

thelancet.com/journals/lanre… The Lancet Respiratory Medicine

1/Amazing progress (Dx & Rx) has been made in the field of ILD. 
That fills us w enthusiasm & hope to keep working to #cureIPF. But, when we looked carefully at the teams driving all these changes, we were surprised:
#genderequity 
thelancet.com/journals/lanre… @LancetRespirMed
account_circle
patientMpower(@patientMpower) 's Twitter Profile Photo

Our platform was designed in consultation with patients and patient organisations. The features are designed to empower people better manage their own conditions

Our #InterstitialLungDisease platform was designed in consultation with #ILD patients and patient organisations. The #app features are designed to empower people better manage their own conditions #VirtualCare #SelfCare
account_circle
Pulmonary Hypertension Journal Club #PAHJC(@JournalClubPH) 's Twitter Profile Photo

OK, let’s kick-start the journal club discussion here of Inhaled Treprostinil for ILD-associated PH. NEJM

2 Rules:
1. Be respectful
2. Declare relevant COI.

Before we discuss results, let’s summarize study and examine the methods. A thread 👇

nejm.org/doi/full/10.10…

account_circle
BCM_Surgery(@BCM_Surgery) 's Twitter Profile Photo

Save the Date! The 2nd Advanced Lung Disease: Novel Therapies and Controversies Conference returns Dec. 5-6, 2020. Webcast live from the TMC. Gabriel Loor BCM Lung Institute American Lung Association Puneet Garcha, MD, MBA
@CHIStLukesNews
Article: bit.ly/2Y5bVBN
THORACon.org

account_circle
Deji Adegunsoye(@drdayjee) 's Twitter Profile Photo

JAMA Network JAMA NetworkOpen PCCM UChicago UChicago Medicine Pulmonary Fibrosis Foundation We had previously observed racial/ethnic disparities in age at (ILD) diagnosis in the Greater Chicago area.

presented at @ATScommunity:
doi.org/10.1164/ajrccm…

…and published in @ERJ erj.ersjournals.com/content/51/6/1…

@JAMANetwork @JAMANetworkOpen @UChicagoPCCM @UChicagoMed @PFFORG We had previously observed racial/ethnic disparities in age at #InterstitialLungDisease (ILD) diagnosis in the Greater Chicago area.

presented at @ATScommunity:
doi.org/10.1164/ajrccm…

…and published in @ERJ erj.ersjournals.com/content/51/6/1…
account_circle